Previous 10 | Next 10 |
I-Mab and Roche Diagnostics Announce Strategic Collaboration to Co-Develop Companion Diagnostics Solutions for I-Mab's Innovative Pipeline at the 4th CIIE PR Newswire SHANGHAI and GAITHERSBURG, Md. , Nov. 8, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq:...
NEW YORK, Nov. 08, 2021 (GLOBE NEWSWIRE) -- DDC Enterprise Limited (the “Company” or “DDC”), a digital publisher and merchandising company that owns and operates the brand DayDayCook, and Ace Global Business Acquisition Limited (“Ace”) (NASDAQ: ACBA...
I-Mab to Present Clinical Data of Lemzoparlimab in Combination with Rituximab in Non-Hodgkins's Lymphoma at ASH 2021 PR Newswire Lemzoparlimab is a differentiated CD47 monoclonal antibody discovered by I-Mab and being developed in collaboration with AbbVie In...
I-Mab Announces Upcoming Participation at November Conferences PR Newswire SHANGHAI and GAITHERSBURG, Md. , Nov. 3, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, develop...
I-Mab Strengthens Senior Executive Team with New Chief Financial Officer and Chief Strategy Officer Appointments - Industry veteran John Long appointed as CFO to lead I-Mab's global corporate finance and capital market activities - Jielun Zhu named as CSO to focus on corpora...
I-Mab Announces Strategic Partnership with Sinopharm in Preparation for Launch of its Innovative Assets in China PR Newswire I-Mab strategic partnership with Sinopharm will covers all aspects of the go-to-market process, including authorization of more than 300 Sinop...
I-Mab Expands U.S. Footprint with New R&D Site in San Diego I-Mab Expands U.S. Footprint with New R&D Site in San Diego PR Newswire - I-Mab will strengthen its global R&D presence, with a new world-class R&D and operational site, located in the hear...
I-Mab Announces IND Approval for Phase 2 Clinical Trial of Efineptakin Alfa in Combination with PD-1 Therapy in China PR Newswire SHANGHAI and GAITHERSBURG, Md. , Oct. 18, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmace...
I-Mab's shares surged up to 15% on positive results from a peer developing a similar new type of cancer treatment, though they later gave back most of those gains. Company has plenty of cash on hand and could soon get more as it seeks a deal to commercialize the drug, uliledlimab, wit...
I-Mab Advances Late-stage Development of Its Differentiated CD38 Antibody Felzartamab (TJ202) in China PR Newswire Completed patient enrollment in phase 3 registrational trial of felzartamab in combination with lenalidomide for second-line treatment of multiple myelo...
News, Short Squeeze, Breakout and More Instantly...
I-Mab Announces Leadership Transitions PR Newswire ROCKVILLE, Md. , July 15, 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB) (the "Company" or "I-Mab"), a U.S.-based, global biotech company, announced today that the Board of Directors of the Company has appointed Mr. ...
I-Mab Appoints Phillip Dennis, MD, PhD, as Chief Medical Officer PR Newswire ROCKVILLE, Md. , June 6 , 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB) (the "Company"), a U.S.-based, global biotech company, exclusively focused on the development and potential commercial...
I-Mab Announces Collaboration with Bristol Myers Squibb to Evaluate Givastomig in a Combination Study for Newly Diagnosed Gastric and Esophageal Cancers PR Newswire I-Mab enters clinical collaboration with Bristol Myers Squibb to evaluate Claudin 18.2 x 4-1BB bispecific anti...